Cancer

Breast cancer treatments more effective now than in the past

(HealthDay)—Comparison of recurrence and outcome patterns shows that current treatments for breast cancer are more effective than previous therapies, according to research published online Nov. 24 in the Journal of Clinical ...

Cancer

Hospital volume not linked to costs of cancer surgery

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

Cancer

Diagnostic criteria developed for cancer-linked weight loss

(HealthDay)—A grading system has been developed for clinically important weight loss (WL) in patients with cancer, which includes the independent prognostic significance of body mass index (BMI) and percent WL, according ...

Cancer

Telephone support intervention beneficial for BRCA carriers

(HealthDay)—A telephone-based, peer-support program can reduce distress and unmet information needs among women with a BRCA1 or BRCA2 mutation, according to a study published online Nov. 17 in the Journal of Clinical Oncology.

Other

Recent increase in reporting of financial conflicts of interest

(HealthDay)—Reporting of financial conflicts of interest (FCOIs) has increased over time in clinical practice guidelines (CPGs) and consensus statements (CSs) for the treatment of common solid tumors, according to research ...

Cancer

Breast cancer markers commonly used for routine surveillance

(HealthDay)—Breast cancer tumor markers are frequently used for routine surveillance in nonmetastatic breast cancer, and their use has been found to increase the number of diagnostic procedures performed as well as the ...

Cancer

Aspirin may cut mortality in nonmetastatic prostate cancer

(HealthDay)—Daily aspirin use, even at low doses, may reduce mortality among men with high-risk nonmetastatic prostate cancer, according to research published online Oct. 20 in the Journal of Clinical Oncology.

Cancer

70-gene signature not cost-effective in breast cancer

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in ...

page 4 from 23